Jay S. Desgrosellier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jay S. Desgrosellier has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Richard Klemke
Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
5 shared publicationsShreyas Labhsetwar
Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
4 shared publicationsAran Zakeri
Department of Pathology, University of California, San Diego, La Jolla, USA
3 shared publicationsDevam Dave
Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
3 shared publicationsQi Sun
Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA
3 shared publicationsSamson Mugisha
Department of Pathology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
3 shared publications
Latest Publications
- Open Access
- 22 April 2025
- Published by Elsevier in Data in Brief
- Vol. 60, 111573
A dataset of chronic nicotine-induced genes in breast cancer cells
- 22 April 2025
- Published by Elsevier in Data in Brief
- Vol. 60, 111573
Open AccessA dataset of chronic nicotine-induced genes in breast cancer cells
- Open Access
- 25 January 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (15) , 1051-1062
S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers
Smoking plays an underappreciated role in breast cancer progression, increasing recurrence and mortality in patients. Here, we show that S100A8/A9 innate immune signaling is a molecular mechanism that identifies smoking-related breast cancers and underlies their enhanced malignancy. In contrast to acute exposure, chronic nicotine increased tumorigenicity and reprogrammed breast cancer cells to express innate immune response genes. This required the α7 nicotinic acetylcholine receptor, which elicited dynamic changes in cell differentiation, proliferation, and expression of secreted cytokines, such as S100A8 and S100A9, as assessed by unbiased scRNA-seq. Indeed, pharmacologic or genetic inhibition of S100A8/A9-RAGE receptor signaling blocked nicotine’s tumor-promoting effects. We also discovered Syntaphilin (SNPH) as an S100A8/A9-dependent gene enriched specifically in estrogen receptor-negative (ER-) cancers from former smokers, linking this response to patient disease. Together, our findings describe a new α7 nAChR-S100A8/A9-Syntaphilin immune signaling module that drives nicotine-induced tumor progression and distinguishes smoking-related patient disease as a distinct subset of aggressive breast cancers.
- 25 January 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (15) , 1051-1062
Open AccessS100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers
Smoking plays an underappreciated role in breast cancer progression, increasing recurrence and mortality in patients. Here, we show that S100A8/A9 innate immune signaling is a molecular mechanism that identifies smoking-related breast cancers and underlies their enhanced malignancy. In contrast to acute exposure, chronic nicotine increased tumorigenicity and reprogrammed breast cancer cells to express innate immune response genes. This required the α7 nicotinic acetylcholine receptor, which elicited dynamic changes in cell differentiation, proliferation, and expression of secreted cytokines, such as S100A8 and S100A9, as assessed by unbiased scRNA-seq. Indeed, pharmacologic or genetic inhibition of S100A8/A9-RAGE receptor signaling blocked nicotine’s tumor-promoting effects. We also discovered Syntaphilin (SNPH) as an S100A8/A9-dependent gene enriched specifically in estrogen receptor-negative (ER-) cancers from former smokers, linking this response to patient disease. Together, our findings describe a new α7 nAChR-S100A8/A9-Syntaphilin immune signaling module that drives nicotine-induced tumor progression and distinguishes smoking-related patient disease as a distinct subset of aggressive breast cancers.
- Open Access
- 13 September 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1450614
Chromosomal instability as an architect of the cancer stemness landscape
Despite a critical role for tumor-initiating cancer stem cells (CSCs) in breast cancer progression, major questions remain about the properties and signaling pathways essential for their function. Recent discoveries highlighting mechanisms of CSC-resistance to the stress caused by chromosomal instability (CIN) may provide valuable new insight into the underlying forces driving stemness properties. While stress tolerance is a well-known attribute of CSCs, CIN-induced stress is distinctive since levels appear to increase during tumor initiation and metastasis. These dynamic changes in CIN levels may serve as a barrier constraining the effects of non-CSCs and shaping the stemness landscape during the early stages of disease progression. In contrast to most other stresses, CIN can also paradoxically activate pro-tumorigenic antiviral signaling. Though seemingly contradictory, this may indicate that mechanisms of CIN tolerance and pro-tumorigenic inflammatory signaling closely collaborate to define the CSC state. Together, these unique features may form the basis for a critical relationship between CIN and stemness properties.
- 13 September 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1450614
Open AccessChromosomal instability as an architect of the cancer stemness landscape
Despite a critical role for tumor-initiating cancer stem cells (CSCs) in breast cancer progression, major questions remain about the properties and signaling pathways essential for their function. Recent discoveries highlighting mechanisms of CSC-resistance to the stress caused by chromosomal instability (CIN) may provide valuable new insight into the underlying forces driving stemness properties. While stress tolerance is a well-known attribute of CSCs, CIN-induced stress is distinctive since levels appear to increase during tumor initiation and metastasis. These dynamic changes in CIN levels may serve as a barrier constraining the effects of non-CSCs and shaping the stemness landscape during the early stages of disease progression. In contrast to most other stresses, CIN can also paradoxically activate pro-tumorigenic antiviral signaling. Though seemingly contradictory, this may indicate that mechanisms of CIN tolerance and pro-tumorigenic inflammatory signaling closely collaborate to define the CSC state. Together, these unique features may form the basis for a critical relationship between CIN and stemness properties.
- Open Access
- 12 July 2024
- Published by Springer Nature in Research Square
S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers
Smoking plays an underappreciated role in breast cancer progression, increasing recurrence and mortality in patients. Here, we show that S100A8/A9 innate immune signaling is a molecular mechanism that identifies smoking-related breast cancers and underlies their enhanced malignancy. In contrast to acute exposure, chronic nicotine increased tumorigenicity and reprogrammed breast cancer cells to express innate immune response genes. This required the α7 nicotinic acetylcholine receptor, which elicited dynamic changes in cell differentiation, proliferation, and expression of secreted cytokines, such as S100A8 and S100A9, as assessed by unbiased scRNA-Seq. Indeed, pharmacologic or genetic inhibition of S100A8/A9-RAGE receptor signaling blocked nicotine’s tumor-promoting effects. We also noted enrichment of S100A9 in cancers from former smokers, along with SNPH, linking this response to patient disease. Together, our findings describe a new α7 nAChR-S100A8/A9 immune signaling module that drives nicotine-induced tumor progression and distinguishes smoking-related patient disease as a distinct subset of aggressive breast cancers.
- 12 July 2024
- Published by Springer Nature in Research Square
Open AccessS100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers
Smoking plays an underappreciated role in breast cancer progression, increasing recurrence and mortality in patients. Here, we show that S100A8/A9 innate immune signaling is a molecular mechanism that identifies smoking-related breast cancers and underlies their enhanced malignancy. In contrast to acute exposure, chronic nicotine increased tumorigenicity and reprogrammed breast cancer cells to express innate immune response genes. This required the α7 nicotinic acetylcholine receptor, which elicited dynamic changes in cell differentiation, proliferation, and expression of secreted cytokines, such as S100A8 and S100A9, as assessed by unbiased scRNA-Seq. Indeed, pharmacologic or genetic inhibition of S100A8/A9-RAGE receptor signaling blocked nicotine’s tumor-promoting effects. We also noted enrichment of S100A9 in cancers from former smokers, along with SNPH, linking this response to patient disease. Together, our findings describe a new α7 nAChR-S100A8/A9 immune signaling module that drives nicotine-induced tumor progression and distinguishes smoking-related patient disease as a distinct subset of aggressive breast cancers.
- Open Access
- 9 October 2023
- Published by Elsevier in Data in Brief
- Vol. 51, 109647
A dataset of chromosomal instability gene signature scores in normal and cancer cells from the human breast
- 9 October 2023
- Published by Elsevier in Data in Brief
- Vol. 51, 109647
Open AccessA dataset of chromosomal instability gene signature scores in normal and cancer cells from the human breast
- Open Access
- 13 January 2022
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1-10
Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1
Breast cancer cells with stem-like properties are critical for tumor progression, yet much about these cells remains unknown. Here, we characterize a population of stem-like breast cancer cells expressing the integrin αvβ3 as transcriptionally related to activated stem/basal cells in the normal human mammary gland. An unbiased functional screen of genes unique to these cells identified the matrix protein TGFBI (BIG-H3) and the transcription factor ZEB1 as necessary for tumorsphere formation. Surprisingly, these genes were not required for cell proliferation or survival, but instead maintained chromosomal stability. Consistent with this finding, CRISPR deletion of either gene synergized with PARP inhibition to deplete αvβ3+ stem-like cells, which are normally resistant to this therapy. Our findings highlight a critical role for TGFBI-ZEB1 protection against genetic stress as a key attribute of activated stem-like cells and suggest that disrupting this ability may enhance their “BRCAness” by increasing sensitivity to PARP inhibitors.
- 13 January 2022
- Published by Springer Nature in npj Breast Cancer
- Vol. 8 (1) , 1-10
Open AccessStem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1
Breast cancer cells with stem-like properties are critical for tumor progression, yet much about these cells remains unknown. Here, we characterize a population of stem-like breast cancer cells expressing the integrin αvβ3 as transcriptionally related to activated stem/basal cells in the normal human mammary gland. An unbiased functional screen of genes unique to these cells identified the matrix protein TGFBI (BIG-H3) and the transcription factor ZEB1 as necessary for tumorsphere formation. Surprisingly, these genes were not required for cell proliferation or survival, but instead maintained chromosomal stability. Consistent with this finding, CRISPR deletion of either gene synergized with PARP inhibition to deplete αvβ3+ stem-like cells, which are normally resistant to this therapy. Our findings highlight a critical role for TGFBI-ZEB1 protection against genetic stress as a key attribute of activated stem-like cells and suggest that disrupting this ability may enhance their “BRCAness” by increasing sensitivity to PARP inhibitors.
- Open Access
- 10 June 2021
- Published by Impact Journals, LLC in Oncoscience
- Vol. 8, 76-79
A precision approach to breast cancer treatment based on cell lineage-specific vulnerabilities
- 10 June 2021
- Published by Impact Journals, LLC in Oncoscience
- Vol. 8, 76-79
Open AccessA precision approach to breast cancer treatment based on cell lineage-specific vulnerabilities
- Open Access
- 1 August 2019
- Published by Elsevier in Cancer Letters
- Vol. 457, 40-46
Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells
- 1 August 2019
- Published by Elsevier in Cancer Letters
- Vol. 457, 40-46
Open AccessCombined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells
- Open Access
- 11 December 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (1) , 531-544
Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis
Breast cancer cells with stem cell properties are key contributors to metastatic disease, and there remains a need to better understand and target these cells in human cancers. Here, we identified rare stem-like cells in patients’ tumors characterized by low levels of the proapoptotic molecule p53-upregulated modulator of apoptosis (PUMA) and showed that these cells play a critical role in tumor progression that is independent of clinical subtype. A signaling axis consisting of the integrin αvβ3, Src kinase, and the transcription factor Slug suppresses PUMA in these cells, promoting tumor stemness. We showed that genetic or pharmacological disruption of αvβ3/Src signaling drives PUMA expression, specifically depleting these stem-like tumor cells; increases their sensitivity to apoptosis; and reduces pulmonary metastasis, with no effect on primary tumor growth. Taken together, these findings point to PUMA as a key vulnerability of stem-like cells and suggest that pharmacological upregulation of PUMA via Src inhibition may represent a strategy to selectively target these cells in a wide spectrum of aggressive breast cancers.
- 11 December 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (1) , 531-544
Open AccessProapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis
Breast cancer cells with stem cell properties are key contributors to metastatic disease, and there remains a need to better understand and target these cells in human cancers. Here, we identified rare stem-like cells in patients’ tumors characterized by low levels of the proapoptotic molecule p53-upregulated modulator of apoptosis (PUMA) and showed that these cells play a critical role in tumor progression that is independent of clinical subtype. A signaling axis consisting of the integrin αvβ3, Src kinase, and the transcription factor Slug suppresses PUMA in these cells, promoting tumor stemness. We showed that genetic or pharmacological disruption of αvβ3/Src signaling drives PUMA expression, specifically depleting these stem-like tumor cells; increases their sensitivity to apoptosis; and reduces pulmonary metastasis, with no effect on primary tumor growth. Taken together, these findings point to PUMA as a key vulnerability of stem-like cells and suggest that pharmacological upregulation of PUMA via Src inhibition may represent a strategy to selectively target these cells in a wide spectrum of aggressive breast cancers.